Pub Date : 2020-06-02DOI: 10.31031/nacs.2020.04.000598
A. Bhattacharjee
{"title":"Repurposing of Anti-diabetic Drug in Cancer Prevention","authors":"A. Bhattacharjee","doi":"10.31031/nacs.2020.04.000598","DOIUrl":"https://doi.org/10.31031/nacs.2020.04.000598","url":null,"abstract":"","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48865746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-06-02DOI: 10.31031/nacs.2020.04.000597
Yi Lu
{"title":"Toll-Like Receptor Agonists in Cancer Therapy","authors":"Yi Lu","doi":"10.31031/nacs.2020.04.000597","DOIUrl":"https://doi.org/10.31031/nacs.2020.04.000597","url":null,"abstract":"","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44967772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-29DOI: 10.31031/NACS.2020.04.000596
A. Arbab, Meser M. Ali
Angiogenesis is a hallmark of glioblastoma (GBM) and remains an important therapeutic target in its treatment, especially for recurrent GBM. GBMs are characterized by the release of vascular endothelial growth factor (VEGF), an important regulator and promoter of angiogenesis. Therefore, antiangiogenic therapies (AATs) targeting VEGF or VEGF receptors (VEGFRs) were designed and thought to be an effective tool for controlling the growth of GBM. However, recent results of different clinical trials using humanized monoclonal antibodies against VEGF (bevacizumab), as well as tyrosine kinase inhibitors (TKIs) that target different VEGFRs alone or in combination with other therapeutic agents demonstrated mixed results, with the majority of reports indicating that GBM developed resistance against antiangiogenic treatments.
{"title":"Glioblastoma: Targeting Angiogenesis and Tyrosine Kinase Pathways.","authors":"A. Arbab, Meser M. Ali","doi":"10.31031/NACS.2020.04.000596","DOIUrl":"https://doi.org/10.31031/NACS.2020.04.000596","url":null,"abstract":"Angiogenesis is a hallmark of glioblastoma (GBM) and remains an important therapeutic target in its treatment, especially for recurrent GBM. GBMs are characterized by the release of vascular endothelial growth factor (VEGF), an important regulator and promoter of angiogenesis. Therefore, antiangiogenic therapies (AATs) targeting VEGF or VEGF receptors (VEGFRs) were designed and thought to be an effective tool for controlling the growth of GBM. However, recent results of different clinical trials using humanized monoclonal antibodies against VEGF (bevacizumab), as well as tyrosine kinase inhibitors (TKIs) that target different VEGFRs alone or in combination with other therapeutic agents demonstrated mixed results, with the majority of reports indicating that GBM developed resistance against antiangiogenic treatments.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":"4 5 1","pages":"398-401"},"PeriodicalIF":0.0,"publicationDate":"2020-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43879267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-04DOI: 10.31031/nacs.2020.04.000593
M. Roy
Association between exposure to high arsenic content and gallbladder cancer is scanty. Few reports suggest that the incidence of gallbladder cancer is high along the Indo-Gangetic belt. Inflammation, which is a causative factor for gallbladder carcinoma can be induced by arsenic. Prognosis of gallbladder cancer is poor. Therefore, it is worthwhile to find a correlation between arsenic exposure and its incidence to identify a population who are at high risk category.
{"title":"Prevalence of Gallbladder Cancer in Arsenic Endemic Areas","authors":"M. Roy","doi":"10.31031/nacs.2020.04.000593","DOIUrl":"https://doi.org/10.31031/nacs.2020.04.000593","url":null,"abstract":"Association between exposure to high arsenic content and gallbladder cancer is scanty. Few reports suggest that the incidence of gallbladder cancer is high along the Indo-Gangetic belt. Inflammation, which is a causative factor for gallbladder carcinoma can be induced by arsenic. Prognosis of gallbladder cancer is poor. Therefore, it is worthwhile to find a correlation between arsenic exposure and its incidence to identify a population who are at high risk category.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43890289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-04DOI: 10.31031/nacs.2021.06.000642
S. Cimpean, K. Bobb, G. Cadière
Associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) is proposed as a surgical option for the patients with no other surgical option with failed portal vein embolization or extremely small future liver remnant. Since the first publication of the technique in 2012, this technique evolved nowadays to partial ALPPS and minimal-invasive ALPPS. Conventional two-stage hepatectomy remains a feasible option for older patients and those with a liver to body-weight-ratio of > 0,4.
{"title":"Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy in 2020","authors":"S. Cimpean, K. Bobb, G. Cadière","doi":"10.31031/nacs.2021.06.000642","DOIUrl":"https://doi.org/10.31031/nacs.2021.06.000642","url":null,"abstract":"Associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) is proposed as a surgical option for the patients with no other surgical option with failed portal vein embolization or extremely small future liver remnant. Since the first publication of the technique in 2012, this technique evolved nowadays to partial ALPPS and minimal-invasive ALPPS. Conventional two-stage hepatectomy remains a feasible option for older patients and those with a liver to body-weight-ratio of > 0,4.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41347203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-29DOI: 10.31031/nacs.2020.04.000592
B. Qu
Tissue response to the radiation is a complex pathophysiological process and is an inherited polygenic trait. Aim of the Radiogenomics studies is to discover related genetic variants that confer tumor or non-tumor tissue radio sensitivity as the target of radio-sensitizing and/or radio-protective agents and to identify specific genetic markers for prognosis or risk prediction. The methods for radiogenomics studies include candidate gene approaches, genome-wide association studies, Next-Generation
{"title":"Methods, Challenges and Future Directions of Radiogenomics","authors":"B. Qu","doi":"10.31031/nacs.2020.04.000592","DOIUrl":"https://doi.org/10.31031/nacs.2020.04.000592","url":null,"abstract":"Tissue response to the radiation is a complex pathophysiological process and is an inherited polygenic trait. Aim of the Radiogenomics studies is to discover related genetic variants that confer tumor or non-tumor tissue radio sensitivity as the target of radio-sensitizing and/or radio-protective agents and to identify specific genetic markers for prognosis or risk prediction. The methods for radiogenomics studies include candidate gene approaches, genome-wide association studies, Next-Generation","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42694424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-21DOI: 10.31031/NACS.2020.04.000591
B. Ramjiawan, A. Maksymiuk, P. Tappia, R. Bux, P. Akhtar, D. Sitar
for Detection of Cancer Bram Ramjiawan1,2, Andrew W Maksymiuk3,4, Paramjit S Tappia1*, Rashid Ahmed Bux5, Parveen S Akhtar6, Donald Miller2 and Daniel S Sitar2,4 1Asper Clinical Research Institute & Office of Clinical Research, Canada 2Department of Pharmacology & Therapeutics, Rady Faculty of Health Sciences, Canada 3Cancer Care Manitoba, Canada 4Department of Internal Medicine, Canada 5BioMark Diagnostics Inc., Canada 6Department of Medical Oncology, Bangladesh Crimson Publishers Wings to the Research Opinion
用于检测癌症Bram Ramjiawan 1,2，Andrew W Maksymiuk3,4，Paramjit S Tappia1*，Rashid Ahmed Bux5，Parveen S Akhtar6，Donald Miller2和Daniel S Sitar2,4 1加拿大临床研究所和临床研究办公室2加拿大拉迪卫生科学学院药理学和治疗学系3加拿大马尼托巴省癌症护理中心4内科部，加拿大5BioMark诊断股份有限公司，加拿大6医学肿瘤科，孟加拉国Crimson出版社研究意见之翼
{"title":"Versatility of Amantadine and Rimantadine for Detection of Cancer","authors":"B. Ramjiawan, A. Maksymiuk, P. Tappia, R. Bux, P. Akhtar, D. Sitar","doi":"10.31031/NACS.2020.04.000591","DOIUrl":"https://doi.org/10.31031/NACS.2020.04.000591","url":null,"abstract":"for Detection of Cancer Bram Ramjiawan1,2, Andrew W Maksymiuk3,4, Paramjit S Tappia1*, Rashid Ahmed Bux5, Parveen S Akhtar6, Donald Miller2 and Daniel S Sitar2,4 1Asper Clinical Research Institute & Office of Clinical Research, Canada 2Department of Pharmacology & Therapeutics, Rady Faculty of Health Sciences, Canada 3Cancer Care Manitoba, Canada 4Department of Internal Medicine, Canada 5BioMark Diagnostics Inc., Canada 6Department of Medical Oncology, Bangladesh Crimson Publishers Wings to the Research Opinion","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42375422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-16DOI: 10.31031/NACS.2020.04.000590
Baofa Yu
Recent years cancer immunological therapy is getting very popular and many new drug have been approved by FDA like PD1 and PDl-1, however, in clinical practice of cancer treatment, it looks very limited efficacy for advanced cancer, so that physician started to use comprehensive plan by combination chemotherapy with PD1 as a novel strategy with a better clinical benefit. Since chemotherapy and radiation therapy always produce the side effect like loss hair, vomit and neutropenia, and surgery is limited for many later stages of cancers, also surgery damages body shapes with functions, esophageal cancer was removed with reconstruction and put stomach into chest and stomach never has normal function; a lot of cases showed surgery can’t be performed because tumor location in special site, like tumor location in posterior vaginal wall or vaginal carnal, surgery just is not allowed to do the procedure, if remove the tumor in these location, it will make a hole to connect to the rectal. Because of the extremely toxic side effects, many cancer patients cannot be successfully completed a surgery or a complete course of chemotherapy or radiation therapy, and some cases even die from the side effects of surgery or chemotherapy or radiation therapy due to a patient’s poor tolerance. The extreme side effects of anti-cancer drugs are often caused by the poor target specificity of such drugs regarding the tumor in the patient’s body. The drugs circulate through most normal organs of patients as well as the intended target tumors (less than 5% of the drug reach the tumor), while over 95% of the drug circulates through the whole body of the patient.
{"title":"A Novel Eclectic Approach for Cancer Therapy with Liquid Knife & Immuno Therapy: UMIPIC, it may Overtake many Surgery, Chemotherapy and Radiation Therapy for all Stages of Solid Tumor","authors":"Baofa Yu","doi":"10.31031/NACS.2020.04.000590","DOIUrl":"https://doi.org/10.31031/NACS.2020.04.000590","url":null,"abstract":"Recent years cancer immunological therapy is getting very popular and many new drug have been approved by FDA like PD1 and PDl-1, however, in clinical practice of cancer treatment, it looks very limited efficacy for advanced cancer, so that physician started to use comprehensive plan by combination chemotherapy with PD1 as a novel strategy with a better clinical benefit. Since chemotherapy and radiation therapy always produce the side effect like loss hair, vomit and neutropenia, and surgery is limited for many later stages of cancers, also surgery damages body shapes with functions, esophageal cancer was removed with reconstruction and put stomach into chest and stomach never has normal function; a lot of cases showed surgery can’t be performed because tumor location in special site, like tumor location in posterior vaginal wall or vaginal carnal, surgery just is not allowed to do the procedure, if remove the tumor in these location, it will make a hole to connect to the rectal. Because of the extremely toxic side effects, many cancer patients cannot be successfully completed a surgery or a complete course of chemotherapy or radiation therapy, and some cases even die from the side effects of surgery or chemotherapy or radiation therapy due to a patient’s poor tolerance. The extreme side effects of anti-cancer drugs are often caused by the poor target specificity of such drugs regarding the tumor in the patient’s body. The drugs circulate through most normal organs of patients as well as the intended target tumors (less than 5% of the drug reach the tumor), while over 95% of the drug circulates through the whole body of the patient.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43591783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-14DOI: 10.31031/NACS.2020.04.000589
Mettler Liselotte, I. Alkatout
While endoscopic gynecological surgery as laparoscopy and hysteroscopy in all its variations of skills, like with single port entry, multiple port entry, conventional or robotically assisted has been universally completely accepted by the medical and patient community this is not at all yet a reality in oncological indications [1]. The article reviews the reality reality of Endoscopic surgery and its application in Gynecological Malignancy diagnosis and treatment focusing endometrial sarcoma, cervical and ovarian cancer.
{"title":"Critical Remarks to Endoscopic Surgery for Endometrial Cancer and Sarcoma, Cervical and Ovarian Cancer Diagnosis and Treatment","authors":"Mettler Liselotte, I. Alkatout","doi":"10.31031/NACS.2020.04.000589","DOIUrl":"https://doi.org/10.31031/NACS.2020.04.000589","url":null,"abstract":"While endoscopic gynecological surgery as laparoscopy and hysteroscopy in all its variations of skills, like with single port entry, multiple port entry, conventional or robotically assisted has been universally completely accepted by the medical and patient community this is not at all yet a reality in oncological indications [1]. The article reviews the reality reality of Endoscopic surgery and its application in Gynecological Malignancy diagnosis and treatment focusing endometrial sarcoma, cervical and ovarian cancer.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41358266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-06DOI: 10.31031/NACS.2020.04.000588
P. K. Dhanyamraju, Yevgeniya Bamme, SinisaDovat, D. Desai
The Hedgehog (Hh) signal transduction pathway is involved in diverse physiological processes such as cell survival, proliferation, differentiation, embryonic development, and fetal determination. Perturbations in this pathway leading to its aberrant activation have been implicated in various cancers including acute myeloid leukemia (AML). AML is a highly complex hematological malignancy resulting due to accumulation of abnormal myeloblasts in the bone marrow leading to bone marrow failure and ultimately death. Recently, the role of hedgehog signaling in AML pathogenesis has been uncovered and thus pharmacological targeting of the hedgehog pathway in AML has become a prime therapeutic option. In this mini-review, we highlight the role of the hedgehog pathway in AML and review the latest drugs as well as possible Hh targets in treating AML.
{"title":"The Role of “Hedgehog Signaling” in AML","authors":"P. K. Dhanyamraju, Yevgeniya Bamme, SinisaDovat, D. Desai","doi":"10.31031/NACS.2020.04.000588","DOIUrl":"https://doi.org/10.31031/NACS.2020.04.000588","url":null,"abstract":"The Hedgehog (Hh) signal transduction pathway is involved in diverse physiological processes such as cell survival, proliferation, differentiation, embryonic development, and fetal determination. Perturbations in this pathway leading to its aberrant activation have been implicated in various cancers including acute myeloid leukemia (AML). AML is a highly complex hematological malignancy resulting due to accumulation of abnormal myeloblasts in the bone marrow leading to bone marrow failure and ultimately death. Recently, the role of hedgehog signaling in AML pathogenesis has been uncovered and thus pharmacological targeting of the hedgehog pathway in AML has become a prime therapeutic option. In this mini-review, we highlight the role of the hedgehog pathway in AML and review the latest drugs as well as possible Hh targets in treating AML.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43583737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：